Showing 1411-1420 of 10594 results for "".
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
https://reachmd.com/programs/project-oncology/dato-dxd-nsclc-tropion-lung01-data/36610/As brain metastases continue to complicate treatment decisions in advanced non-small cell lung cancer (NSCLC), recent evidence is shifting the therapeutic landscape. Data from a post-hoc analysis of TROPION-Lung01—presented at the 2025 World Conference on Lung Cancer—demonstrate meaningful intracraSustaining Vision: Empowering Optometry for Tomorrow’s Retinal Care
https://reachmd.com/cme/ophthalmology/Sustaining-Vision-Empowering-Optometry-for-Tomorrows-Retinal-Care/32392/Join Drs. Khanani, Sheth, and Vajzovic, to learn how to educate patients about alternative treatment options for retinal diseases.Coming & Going: November/December 2022
https://reachmd.com/ma-issues-index/2022-nov-dec/coming-going-novemberdecember-2022/35236/Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
https://reachmd.com/clinical-practice/cardiology/hypertrophic-cardiomyopathy-overcoming-practical-barriers-to-treatment-in-the-era-of-myosin-inhibitors/56414/Dive into practical barriers to myosin inhibitor use in HCM and learn strategies to support timely initiation and access for eligible patients.Optimizing Multidisciplinary Approaches in the Guideline-Driven Management of Cervical and Endometrial Cancers
https://reachmd.com/programs/cme/optimizing-multidisciplinary-approaches-in-the-guideline-driven-management-of-cervical-and-endometrial-cancers/37236/Explore clinical data and guideline-driven strategies for the multidisciplinary management of cervical and endometrial cancers.Treatment of Developmental/Epileptic Encephalopathy With Spike-Wave Activation in Sleep
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/treatment-of-developmentalepileptic-encephalopathy-with-spike-wave-activation-in-sleep/39968/Developmental/epileptic encephalopathy with spike-wave activation in sleep is a unique electroclinical entity accompanied by cognitive, developmental, or behavioral stagnation or regression.Integrating IV Iron into Cancer Care: An Expert Overview of Best Practices
https://reachmd.com/programs/cme/integrating-iv-iron-into-cancer-care-an-expert-overview-of-best-practices/35585/Designed as a dynamic, intensive, and innovative web-based activity, this session will take learners on an in-depth exploration of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states of vast clinical significance, emphasizing the robust prevalence, pathophysiology, anAdvances in the Management of Difficult-to-Treat Asthma
https://reachmd.com/programs/cme/advances-in-the-management-of-difficult-to-treat-asthma/10893/This multidisciplinary, virtual roundtable brings together clinicians and a patient to discuss clinical aspects of care in people with asthma.Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
https://reachmd.com/programs/cme/chairpersons-perspective-evidence-informed-clinical-decision-making-in-her2-overexpressed-and-trop2-targeted-nsclc/39894/Study HER2 IHC testing, efficacy, and NCCN guidance supporting ADC sequencing for HER2-overexpressed NSCLC and TROP2-directed ADCs for EGFR-TKI–resistant NSCLC.On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
https://reachmd.com/programs/project-oncology/io-therapies-for-patients-with-her2-negative-ggejc/35513/For patients who are diagnosed with metastatic gastric cancer, the five-year overall survival rate is roughly seven percent, underscoring the need for additional treatment options.1 Fortunately, there has been advancement in gastric cancer care, including the FDA approval of tislelizumab plus platin